AU2020242042A1 - Monoclonal antibodies for prevention and treatment of herpes simplex viral infections - Google Patents

Monoclonal antibodies for prevention and treatment of herpes simplex viral infections Download PDF

Info

Publication number
AU2020242042A1
AU2020242042A1 AU2020242042A AU2020242042A AU2020242042A1 AU 2020242042 A1 AU2020242042 A1 AU 2020242042A1 AU 2020242042 A AU2020242042 A AU 2020242042A AU 2020242042 A AU2020242042 A AU 2020242042A AU 2020242042 A1 AU2020242042 A1 AU 2020242042A1
Authority
AU
Australia
Prior art keywords
seq
antibody
antigen
variable region
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020242042A
Other languages
English (en)
Inventor
Clare BURN
Betsy C. Herold
William R. Jacobs Jr.
Garnett Kelsoe
Masayuki Kuraoka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Albert Einstein College of Medicine
Duke University
Original Assignee
Albert Einstein College Medicine
Albert Einstein College of Medicine
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albert Einstein College Medicine, Albert Einstein College of Medicine, Duke University filed Critical Albert Einstein College Medicine
Publication of AU2020242042A1 publication Critical patent/AU2020242042A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/085—Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
    • C07K16/087—Herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2020242042A 2019-03-19 2020-03-19 Monoclonal antibodies for prevention and treatment of herpes simplex viral infections Pending AU2020242042A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962820495P 2019-03-19 2019-03-19
US62/820,495 2019-03-19
PCT/US2020/023600 WO2020191181A1 (en) 2019-03-19 2020-03-19 Monoclonal antibodies for prevention and treatment of herpes simplex viral infections

Publications (1)

Publication Number Publication Date
AU2020242042A1 true AU2020242042A1 (en) 2021-09-16

Family

ID=70285944

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020242042A Pending AU2020242042A1 (en) 2019-03-19 2020-03-19 Monoclonal antibodies for prevention and treatment of herpes simplex viral infections

Country Status (9)

Country Link
US (1) US12459987B2 (enExample)
EP (1) EP3941524A1 (enExample)
JP (1) JP7835392B2 (enExample)
KR (1) KR20210141948A (enExample)
CN (2) CN113661176B (enExample)
AU (1) AU2020242042A1 (enExample)
CA (1) CA3133862A1 (enExample)
IL (1) IL286415A (enExample)
WO (1) WO2020191181A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114805579B (zh) * 2022-06-08 2023-06-06 郑州大学 一种抗人ace2蛋白单克隆抗体、核酸分子及应用
TWI876557B (zh) * 2022-09-30 2025-03-11 臺北醫學大學 用於前列腺癌診斷和早期發病的單株抗體
CN119751660B (zh) * 2024-12-02 2026-04-03 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 一种猫麻疹病毒特异性单克隆抗体及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
AU1866895A (en) 1994-01-04 1995-08-01 Scripps Research Institute, The Human monoclonal antibodies to herpes simplex virus and methods therefor
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
EP2308895A1 (en) * 2009-10-01 2011-04-13 Universität Duisburg-Essen Anti-HSV antibody
ES2843277T3 (es) 2014-06-26 2021-07-16 Heidelberg Immunotherapeutics Gmbh Aplicación tópica para un anticuerpo anti-VHS
JP2020504105A (ja) 2016-12-19 2020-02-06 グレンマーク・ファーマシューティカルズ・エスエー 新規なｔｎｆｒアゴニストおよびその使用
CN111148832A (zh) 2017-08-30 2020-05-12 Km生物医薬股份公司 抗HSV gB单克隆抗体或其抗原结合片段

Also Published As

Publication number Publication date
WO2020191181A9 (en) 2020-12-10
US12459987B2 (en) 2025-11-04
CN113661176A (zh) 2021-11-16
JP7835392B2 (ja) 2026-03-25
KR20210141948A (ko) 2021-11-23
IL286415A (en) 2021-10-31
CA3133862A1 (en) 2020-09-24
CN113661176B (zh) 2025-02-18
JP2022525535A (ja) 2022-05-17
CN119899260A (zh) 2025-04-29
EP3941524A1 (en) 2022-01-26
WO2020191181A1 (en) 2020-09-24
US20220162291A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
US12497450B2 (en) Claudin 6 antibodies and uses thereof
US20250034248A1 (en) Monoclonal antibodies against human tim-3
WO2018113258A1 (zh) 抗pd-1抗体及其用途
EA036396B1 (ru) Анти-ctla4 моноклональное антитело или его антигенсвязывающий фрагмент, фармацевтическая композиция и применение
EP2308895A1 (en) Anti-HSV antibody
US12459987B2 (en) Monoclonal antibodies for prevention and treatment of herpes simplex viral infections
EP4330278A1 (en) Human neutralizing monoclonal antibodies against sars-cov-2 and uses thereof
CN104603149A (zh) 与预防和治疗狂犬病感染相关的组合物和方法
US20240262894A1 (en) Antibody against respiratory syncytial virus and use thereof
US20220340674A1 (en) Method for the production of bispecific fcyriii x cd30 antibody construct
US20240002500A1 (en) Anti-TIGIT Antibody or Antigen-Binding Fragment Thereof
EP2879706B1 (en) Novel anti-plasmodium parasite antibodies
US20250297026A1 (en) Therapeutic antibodies
CN113150150B (zh) Tim3结合分子及其应用
WO2019200255A1 (en) High-affinity mycobacterium tuberculosis capsule-specific human monoclonal antibody
US20240084039A1 (en) Antibody variable domains and antibodies having decreased immunogenicity
RU2786434C2 (ru) Антитело к tigit и его использование
AU2024275787A1 (en) Antibody variable domains and antibodies having decreased immunogenicity
CN117736314A (zh) 针对SARS-CoV-2和其变异株的中和抗体及其用途